Sage Therapeutics Surges: A Little Bit Of Data Goes A Long Way
February 13, 2017 at 12:27 PM EST
Sage Therapeutics ( SAGE ) scored another victory today for its pipeline of depression treatments. The drug maker’s share price soared more than 15% after it unveiled a small slice of data from its phase II study of SAGE217 in major depressive disorder. BMO Capital Markets analyst Gary Nachman explained why:
